Primary aldosteronism;Hiperaldosteronismo primario

Revista Medica de Chile

Volumn 136, Issue 7, 2008, Pages 905-914

  Fardella B , Carlos E ^a   Mosso, Lorena M ^a   Carvajal, Cristian A ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Aldosterone; Hyperaldosteronism; Hypertension

Indexed keywords

ALDOSTERONE; RENIN;

BLOOD; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MASS SCREENING; METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECRETION;

ALDOSTERONE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MASS SCREENING; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 51849122006     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. KEARNEY PM, WHELTON M, REYNOLDS K, MUNTNER P, WHELTON PK, HE J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
2. JACKSON RV, LAFFERTY A, TORPY DJ, STRATAKIS C. New genetic insights in familial hyperaldosteronism. Ann N Y Acad Sci 2002; 970: 77-88.
3. CONN JW, COHEN EL, ROVNER DR, NESBIT RM. Normokalemic Primary Aldosteronism. A Detectable Cause of Curable "Essential" Hypertension. JAMA 1965; 193: 200-6.
4. TUCKER RM, LABARTHE DR. Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 through 1975. Mayo Clin Proc 1977; 52: 549-5.
5. BLUMENFELD JD, SEALEY JE, SCHLUSSEL Y, VAUGHAN ED JR, SOS TA, ATLAS SA ET AL. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877-85.
6. MULATERO P, STOWASSER M, LOH KC, FARDELLA CE, GORDON RD, MOSSO L ET AL. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-50.
7. FARDELLA CE, MOSSO L, GÓMEZ- SÁNCHEZ C, CORTÉS P, SOTO J, GÓMEZ L ET AL. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-7.
8. LIM PO, DOW E, BRENNAN G, JUNG RT, MACDONALD TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-5.
9. LOH KC, KOAY ES, KHAW MC, EMMANUEL SC, YOUNG WF JR. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-9.
10. NISHIKAWA T, OMURA M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000; 54 Suppl 1: 83s-85s.
11. RAYNER BL, OPIE LH, DAVIDSON JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000; 90: 394-400.
12. GALLAY BJ, AHMAD S, XU L, TOIVOLA B, DAVIDSON RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705.
13. SCHWARTZ GL, CHAPMAN AB, BOERWINKLE E, KISABETH RM, TURNER ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002; 48: 1919-23.
14. CALHOUN DA, NISHIZAKA MK, ZAMAN MA, THAKKAR RB, WEISSMANN P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-6.
15. MOSSO L, CARVAJAL C, GONZÁLEZ A, BARRAZA A, AVILA F, MONTERO J ET AL. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-5.
16. ROSSI E, REGOLISTI G, NEGRO A, SANI C, DAVOLI S, PERAZZOLI F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902.
17. STOWASSER M, GORDON RD, GUNASEKERA TG, COWLEY DC, WARD G, ARCHIBALD C ET AL. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003; 21: 2149-57.
18. OMURA M, SAITO J, YAMAGUCHI K, KAKUTA Y, NISHIKAWA T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193-202.
19. FARDELLA C, CARVAJAL C, MOSSO L. Primary Hyperaldosteronism in the Hypertensive Disease. Curr Hypertens Reviews 2006; 2: 36-40.
20. KAPLAN NM. Cautions over the current epidemic of primary aldosteronism. Lancet 2001; 357: 953-4.
21. PITT B, ZANNAD F, REMME WJ, CODY R, CASTAIGNE A, PÉREZ A ET AL. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
22. PITT B, REMME W, ZANNAD F, NEATON J, MARTÍNEZ F, RONIKER B ET AL. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
23. MILLIEZ P, GIRERD X, PLOUIN PF, BLACHER J, SAFAR ME, MOURAD JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-8.
24. FALLO F, VEGLIO F, BERTELLO C, SONINO N, DELLA MEA P, ERMANI M ET AL. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-9.
25. COOPER ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004; 17: 16S-20S; quiz A2-4.
26. ARIMA S, KOHAGURA K, XU HL, SUGAWARA A, ABE T, SATOH F ET AL. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-63.
27. ARIMA S, KOHAGURA K, XU HL, SUGAWARA A, URUNO A, SATOH F ET AL. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 2004; 43: 352-7.
28. ROCHA R, FUNDER JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002; 970: 89-100.
29. MORNET E, DUPONT J, VITEK A, WHITE PC. Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem 1989; 264: 20961-7.
30. GANGULY A, MELADA GA, LUETSCHER JA, DOWDY AJ. Control of plasma aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia. J Clin Endocrinol Metab 1973; 37: 765-75.
31. VALLOTTON MB. Primary aldosteronism. Part II. Differential diagnosis of primary hyperaldosteronism and pseudoaldosteronism. Clin Endocrinol (Oxf) 1996; 45: 53-60.
32. VALLOTTON MB. Primary aldosteronism. Part I. Diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf) 1996; 45: 47-52.
33. GORDON RD. Primary aldosteronism. J Endocrinol Invest 1995; 18: 495-511.
34. PASCOE L, CURNOW KM, SLUTSKER L, CONNELL JM, SPEISER PW, NEW MI ET AL. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 1992; 89: 8327-31.
35. TORPY DJ, GORDON RD, LIN JP, HUGGARD PR, TAYMANS SE, STOWASSER M ET AL. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 1998; 83: 3214-8.
36. ELPHINSTONE MS, GORDON RD, SO A, JESKE YW, STRATAKIS CA, STOWASSER M. Genomic structure of the human gene for protein kinase A regulatory subunit R1-beta (PRKAR1B) on 7p22: no evidence for mutations in familial hyperaldosteronism type II in a large affected kindred. Clin Endocrinol (Oxf) 2004; 61: 716-23.
37. CORTÉS P, FARDELLA C, OESTREICHER E, GAC H, MOSSO L, SOTO J ET AL. [Excess of mineralocorticoids in essential hypertension: clinical-diagnostic approach]. Rev Méd Chile 2000; 128: 955-61.
38. MCKENNA TJ, SEQUEIRA SJ, HEFFERNAN A, CHAMBERS J, CUNNINGHAM S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73: 952-7.
39. MONTERO J, SOTO J, FARDELLA C, FORADORI A, VALDÉS G. [Measurement of low levels of plasma renin activity. A methodological improvement]. Rev Méd Chile 1998; 126: 151-4.
40. STREETEN DH, TOMYCZ N, ANDERSON GH. Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 1979; 67: 403-13.
41. nd ed. Philadelphia: JB Lippincott Company 1995: 716-29.
42. WISGERHOF M, BROWN RD, HOGAN MJ, CARPENTER PC, EDIS AJ. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism. J Clin Endocrinol Metab 1981; 52: 195-8.
43. GANGULY A. Primary aldosteronism. N Engl J Med 1998; 339: 1828-34.
44. IRONY I, KATER CE, BIGLIERI EG, SHACKLETON CH. Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990; 3: 576-82.
45. WILLIAMS GH, TUCK ML, ROSE LI, DLUHY RG, UNDERWOOD RH. Studies of the control of plasma aldosterone concentration in normal man. 3. Response to sodium chloride infusion. J Clin Invest 1972; 51: 2645-52.
46. DLUHY RG, LIFTON RP. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 1995; 60: 48-51.
47. LITCHFIELD WR, NEW MI, COOLIDGE C, LIFTON RP, DLUHY RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997; 82: 3570-3.
48. MULATERO P, VEGLIO F, PILON C, RABBIA F, ZOCCHI C, LIMONE P ET AL. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998; 83: 2573-5.
49. FARDELLA CE, PINTO M, MOSSO L, GÓMEZ-SÁNCHEZ C, JALIL J, MONTERO J. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. J Clin Endocrinol Metab 2001; 86: 4805-7.
50. MOSSO L, GÓMEZ-SÁNCHEZ CE, FOECKING MF, FARDELLA C. Serum 18-hydroxycortisol in primary aldosteronism, hypertension, and normotensives. Hypertension 2001; 38: 688-91.
51. LIFTON RP, DLUHY RG, POWERS M, RICH GM, COOK S, ULICK S ET AL. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262-5.
52. JONSSON JR, KLEMM SA, TUNNY TJ, STOWASSER M, GORDON RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995; 207: 565-71.
53. MACCONNACHIE AA, KELLY KF, MCNAMARA A, LOUGHLIN S, GATES LJ, INGLIS GC et al. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab 1998; 83: 4328-31.
54. CONNELL J, HAITES N, KENNEY P, LEE J. The adrenals. In: Lee JKT, Sager SS, Stanley RJ, JP H, eds. Computed body tomography with MRI correlation. Philadelphia: Lippincott-Raven Press 1998: 1171-208.
55. REZNEK RH, ARMSTRONG P. The adrenal gland. Clin Endocrinol (Oxf) 1994; 40: 561-76.
56. LÓPEZ JM, FARDELLA C, ARTEAGA E, MICHAUD P, RODRÍGUEZ JA, CRUZ F. Adrenal macrotumors diagnosed by computed tomography. J Endocrinol Invest 1990; 13: 581-5.
57. PHILLIPS JL, WALTHER MM, PEZZULLO JC, RAYFORD W, CHOYKE PL, BERMAN AA ET AL. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000; 85: 4526-33.
58. GAGNER M, POMP A, HENIFORD BT, PHARAND D, LACROIX A. Laparoscopic adrenalectomy: lessons learned from 100 consecutive procedures. Ann Surg 1997; 226: 238-46; discussion 46-7.
59. SHENKER Y. Medical treatment of low-renin aldosteronism. Endocrinol Metab Clin North Am 1989; 18: 415-42.
60. STOWASSER M, BACHMANN AW, HUGGARD PR, ROSSETTI TR, GORDON RD. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 2000; 85: 3313-8.